Navigation Links
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Date:4/15/2013

SAN DIEGO, April 15, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced that David R. Parkinson , M.D., has been appointed to the company's board of directors. Dr. Parkinson is a venture partner at New Enterprise Associates, a position he has held since 2012, and a member of the board of directors for Threshold Pharmaceuticals, a publicly-traded oncology company, and Zyngenia, Inc. He served as a director of Facet Biotech through its acquisition by Abbott in 2010. 

Prior to joining New Enterprise Associates, Dr. Parkinson was president and chief executive officer of Nodality, a biotechnology company focused on personalized medicine. Before this, he held positions as senior vice president of oncology research at Biogen Idec, vice president of oncology development at Amgen, Inc, and vice president of global clinical oncology development at Novartis Corporation. Dr. Parkinson previously held multiple positions with the National Cancer Institute from 1990 to 1997, including chief of the Investigational Drug Branch and associate director of the Cancer Therapy Evaluation Program. He has also served on the National Cancer Policy Forum of the Institute of Medicine and is a past president of the International Society of Biological Therapy. He is a past Chairman of the FDA's Biologics Advisory Committee and member of the FDA Science Board, and is a recipient of the FDA's Cody Medal .  Dr. Parkinson received his medical doctorate from the University of Toronto Faculty of Medicine, with internal medicine and hematology/oncology training at McGill University in Montreal and at New England Medical Center in Boston. He has held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center at Tufts University School of Medicine.

"David brings to Ambit extensive medical and industry experience in oncology, which we believe will bring an appropriate perspective for Ambit at this stage," said Michael Martino , President and CEO of Ambit. "We look forward to his contributions toward the development of quizartinib and the rest of our pipeline."

Added Dr. Parkinson, "I look forward to serving as a director and working with the board and management team to help advance the potentially important new therapeutic agents in the Ambit pipeline."

About Ambit Biosciences

Ambit is a privately held biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Contacts:
Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com  
david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
2. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
3. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
4. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
5. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
6. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
7. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
8. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
9. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
10. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
11. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... ... 03, 2020 , ... In Partnership with the Smiles for Everyone Foundation ... at its Burleson, TX office on February 8th. , Dental services provided include same-day ... and extractions . For more information, please visit the Monarch Dental website ...
(Date:1/3/2020)... ... 03, 2020 , ... American actor, Laurence Fishburne, is well-known for his performances ... most know him for the movies he takes part in, he is also the ... explores a vast range of topics to educate its viewers about many issues taking ...
(Date:12/31/2019)... ... December 31, 2019 , ... ... to its Scientific Advisory Board. NanoFUSE Biologics offers a biologically enhanced synthetic therapeutic, ... medical device. , President of NanoFUSE Biologics, Jake Lubinski, said, “We’re fortunate to ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... 2020 , ... Sigma Theta Tau International Honor Society of Nursing (Sigma) was ... awards are regarded as one of the most important and prestigious designations of excellence ... Year competition has recognized Sigma for the last 11 consecutive years. , The following ...
(Date:1/10/2020)... , ... January 10, 2020 , ... ... has announced that it will be attending the HIMSS (Healthcare Information and Management ... , HIMSS is the can’t-miss health information and technology event of the year, ...
(Date:1/8/2020)... ... 08, 2020 , ... Mirror Mirror Beauty Boutique ... of Memorial Readers’ Choice Awards. Located adjacent to Vitenas Cosmetic Surgery, the ... Memorial reflects Mirror Mirror Beauty Boutique’s commitment to the hottest noninvasive trends that ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... and services, today identified six trends that will significantly impact the point of ... “Arguably, the time shared between a provider and patient is the most important ...
(Date:1/7/2020)... Pa. (PRWEB) , ... January 07, 2020 , ... Iconic ... musical talent and being one of the most successful female artists of all time, ... started her first Las Vegas residency and shared in interviews her secrets to making ...
Breaking Medicine News(10 mins):